2402: Pre-TED Disease Classification

The Pre-TED Form is now required for all transplants, including subsequent transplants on the comprehensive report form track.

All transplant centers participating in the CIBMTR must submit a Pre-TED Disease Classification Form (Form 2402) for each allogeneic (related or unrelated) hematopoietic cell transplant (HCT). The Pre-TED Disease Classification Form is a requirement of the SCTOD for all United States transplant centers when either the stem cell donation or the transplant occurs within the United States. For more information regarding the SCTOD, see General Instructions, Stem Cell Therapeutics Outcomes Database.

Although data regarding recipients receiving autologous HCT are not required to be submitted as part of the C.W. Bill Young Transplant Program, the CIBMTR is highly committed to collecting data on these recipients for research studies. Centers choosing to report autologous data to the CIBMTR must report on all autologous transplants performed at their center. For more information regarding data reporting for autologous HCT, see General Instructions, Autologous Hematopoietic Stem Cell Transplant.

The Pre-TED Disease Classification Form may be submitted to the CIBMTR up to two weeks prior to the start of the recipient’s preparative regimen (see Helpful Hint below). The Pre-TED Disease Classification Form is due the day of the HCT (day 0), and is past due if not received by that date.

The Pre-TED Disease Classification is designed to capture important details regarding the recipient’s primary disease for which the reported HCT is being given. Key reporting areas differ depending on the disease reported (question 1), but may include disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.

Helpful Hint:
In order to avoid having to make changes to the HCT date, complete the data for the Pre-TED Disease Classification Form (in FormsNet3 or on paper), but do not submit the form until the first dose of the preparative regimen is given.

For recipients receiving a subsequent HCT:
Transplant centers must submit a Pre-TED Disease Classification Form for all subsequent HCTs; this includes recipients assigned to the TED Forms and the Comprehensive Report Forms by the form selection algorithm.
For the majority of subsequent HCTs, the recipient will remain on the original follow-up form track assigned by the form selection algorithm. For more information regarding center type and the form selection algorithm, see Section 1 in the Center Reference Guide. A recipient may need to change tracks if enrolled on a study that requires comprehensive forms.

For recipients of multiple transplants, transplant centers are not granted access to the new Pre-TED Disease Classification Form in FormsNet3 until the Post-TED (Form 2450) or Post-Infusion Data Form (Form 2100) from the previous transplant has been completed.

Transplant centers can use the FormsNet3 application to determine if a Pre-TED is due by either: 1) accessing the Forms Due Report, or 2) entering the recipient’s unique ID (CRID) in the Patient Forms Due field.

Links to Sections of the Form:
Q1-2: Primary Disease for HCT
Q3-63: Acute Myelogenous Leukemia
Q64-106: Acute Lymphoblastic Leukemia
Q107-110: Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms
Q111-121: Chronic Myelogenous Leukemia
Q122-215: Myelodysplastic / Myeloproliferative Diseases
Q216-222: Other Leukemia
Q223-225: Hodgkin Lymphoma
Q226-231: Non-Hodgkin Lymphoma
Q232-263: Multiple Myeloma / Plasma Cell Disorder
Q264-265: Solid Tumors
Q266-267: Severe Aplastic Anemia
Q268-270: Inherited Abnormalities of Erythrocyte Differentiation or Function
Q271-273: Disorders of Immune System
Q274-275: Inherited Abnormalities of Platelets
Q276-277: Inherited Disorders of Metabolism
Q278-279: Histocytic Disorders
Q280-287: Autoimmune Diseases
Q288: Other Disease

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
<table>
<thead>
<tr>
<th>Date</th>
<th>Manual Section</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/5/17</td>
<td>2402: Pre-TED Disease Classification</td>
<td>Modify</td>
<td>Updated the instruction for question 262 by adding the text in red below. *Indicate the disease status of the PCD at the last evaluation prior to the start of the preparative regimen. If the primary disease is Amyloidosis <em>or</em> POEMS, report “Not applicable” and go to the signature line.</td>
</tr>
<tr>
<td>2/20/17</td>
<td>2402: Pre-TED Disease Classification</td>
<td>Modify</td>
<td>Updated the multiple myeloma diagnostic criteria provided in the instructions for questions 232-233 to match the IMWG criteria released October 2015.</td>
</tr>
<tr>
<td>1/31/2017</td>
<td>2402: Pre-TED Disease Classification</td>
<td>Modify</td>
<td>Version 1 of the 2402: Pre-TED: Disease Classification section of the Forms Instructions Manual released. Version 1 corresponds to revision 1 of the Form 2402.</td>
</tr>
</tbody>
</table>
Q1-2: Primary Disease for HCT

Disease Classification Questions
The newest versions of the TED Forms use the World Health Organization (WHO) disease classifications. The Disease Classification questions contain all of the established WHO disease types and subtypes. The “other, specify” category should be used only if the recipient’s disease is not one of the listed options. For more information regarding disease classification, consult a transplant physician, contact your center’s CIBMTR CRC, or visit the WHO website at: http://www.who.int/classifications/icd/en/.

Several of the Disease Classification questions ask for “Status at Transplantation.” Although there are many interpretations of disease response criteria, **when reporting data to the CIBMTR, use the guidelines in this manual to determine disease status.** A majority of the disease response criteria are established by an international working group. Citations of resources used to define disease responses are included where applicable.

If the recipient’s status is unclear, consult with the transplant physician for further information or contact your center’s CIBMTR CRC.

Malignant vs. Non-Malignant
Malignant diseases involve cells dividing without control that can spread to other parts of the body through blood and lymph systems. These diseases are usually characterized by unlimited, aggressive growth, invasion of surrounding tissues, and metastasis.

Non-malignant diseases involve cell overgrowth, but lack the malignant properties of cancer.

The CIBMTR database disease codes are represented in parentheses after the disease subtype on the Disease Classification questions and can be helpful in mapping diagnosis [e.g., Myeloid Sarcoma (295)], and determining if the disease is malignant or non-malignant. Disease codes (10-299) indicate a malignant disease, with the exception of Paroxysmal Nocturnal Hemoglobinuria (PNH) (56). A disease code of (300) or above indicates a non-malignant disease, with the exception of disease code (900), which could indicate either a malignant or non-malignant disease.

If the indication for HCT is due to a combination of diseases or a transformation of one disease to another, it may be necessary to report multiple disease classifications. The tables below list how common examples of disease combinations and transformations should be reported using the Disease Classification questions.

| Disease Combinations | Report Primary Disease as: | Report disease diagnosis date of: | Complete multiple disease sections of the Pre-TED? |

---

1 Common Disease Combinations

CIBMTR Forms Instruction Manual: Form 2402: Disease Classification
Forms Revision 1, Manual Version 1
Retired 7/27/17
Common Disease Transformations

<table>
<thead>
<tr>
<th>Disease Transformation</th>
<th>Report primary disease as:</th>
<th>Report disease diagnosis date of:</th>
<th>Complete multiple disease sections on the Pre-TED?</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS or MPS to AML</td>
<td>AML</td>
<td>AML</td>
<td>Yes- AML and MDS/MPN</td>
</tr>
<tr>
<td>JMML to AML</td>
<td>AML</td>
<td>AML</td>
<td>Yes- AML and MDS/MPN (select questions only)</td>
</tr>
<tr>
<td>NHL to another NHL</td>
<td>Second NHL diagnosis</td>
<td>First NHL diagnosis</td>
<td>No</td>
</tr>
<tr>
<td>HL to NHL</td>
<td>NHL</td>
<td>HL</td>
<td>No</td>
</tr>
<tr>
<td>CLL to NHL (i.e., Richter’s Syndrome)</td>
<td>NHL</td>
<td>CLL</td>
<td>Yes- Other Leukemias and NHL</td>
</tr>
</tbody>
</table>

1 AML=Acute Myelogenous Leukemia; AMY=Amyloidosis; CLL=Chronic Lymphocytic Leukemia; FAN=Fanconi Anemia; MDS=Myelodysplastic Syndrome; MPS=Myeloproliferative Disease; MYE=Multiple Myeloma; NHL=Non-Hodgkin Lymphoma; SAA=Severe Aplastic Anemia.

2 Ensure that the disease process is a transformation from Hodgkin lymphoma to Non-Hodgkin lymphoma (typically diffuse large B-cell lymphoma), rather than the distinct entity “B-cell lymphoma, unclassifiable, with features indeterminate between DLBCL and classical Hodgkin Lymphoma.”

**Question 1: Date of diagnosis for primary disease for HCT:**

The date of diagnosis is important because the interval between diagnosis and HCT is often a significant indicator for the recipient’s prognosis post-HCT.

Report the date of the first pathological diagnosis (e.g., bone marrow or tissue biopsy) of the disease. Enter the date the sample was collected for examination. If the diagnosis was determined at an outside center, and no documentation of a pathological or laboratory assessment is available, the dictated date of diagnosis within a physician note may be reported. Do not report the date symptoms first appeared.

If the recipient was diagnosed prenatally (*in utero*), report the date of birth as the date of diagnosis.
If the exact pathological diagnosis date is not known, use the process described in General Instructions, Guidelines for Completing Forms.

If this is a subsequent HCT for a new malignancy (or other new indication), report the date of diagnosis of the new malignancy.

**Question 2: What was the primary disease for which the HCT was performed?**

From the list provided, select the primary disease for which the recipient is receiving the HCT and continue with the appropriate disease classification questions

- Q3-63: Acute Myelogenous Leukemia
- Q64-106: Acute Lymphoblastic Leukemia
- Q107-110: Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms
- Q111-121: Chronic Myelogenous Leukemia
- Q122-215: Myelodysplastic / Myeloproliferative Diseases
- Q216-222: Other Leukemia
- Q223-225: Hodgkin Lymphoma
- Q226-231: Non-Hodgkin Lymphoma
- Q232-263: Multiple Myeloma / Plasma Cell Disorder
- Q264-265: Solid Tumors
- Q266-267: Severe Aplastic Anemia
- Q268-270: Inherited Abnormalities of Erythrocyte Differentiation or Function
- Q271-273: Disorders of Immune System
- Q274-275: Inherited Abnormalities of Platelets
- Q276-277: Inherited Disorders of Metabolism
- Q278-279: Histiocytic Disorders
- Q280-287: Autoimmune Diseases
- Q288: Other Disease
Acute Myelogenous Leukemia (AML) is a cancer of the white blood cells. It is characterized by the rapid proliferation of abnormal, immature myelocytes, known as myeloblasts, in the bone marrow. This accumulation of blasts in the marrow prevents the formation of healthy red blood cells, white blood cells, and/or platelets. Normal myeloblasts develop into neutrophils, basophils, and eosinophils, which are all white blood cells that fight infection. In AML, the leukemic myeloblasts do not fully develop and are unable to fight infection. The symptoms of AML result from a drop in red blood cell, platelet, and normal white blood cell counts caused by the replacement of normal bone marrow with leukemic cells.

Certain prognostic indicators are associated with poorer outcomes. These include advanced age (50+ years of age), AML arising from MDS or secondary/therapy-related AML, and certain genetic mutations that are described in greater detail later in this manual.

**Question 3: Specify the AML classification**

Indicate the disease classification at diagnosis; the older FAB classifications are shown in parenthesis, e.g., (M0).

Report the most specific entity that applies to the recipient. For example, if the recipient was classified using both cytogenetic data and the M5 FAB classification, the more specific cytogenetic data should be reported for classification purposes.

**Question 4: Did AML transform from MDS or MPN?**

AML often evolves from MDS or MPN. This transformation is typically distinguished by the percentage of blasts in the bone marrow.

AML that transforms from MDS or MPN has a lower survival prognosis because of the association with unfavorable cytogenetic abnormalities.

AML can also evolve from Juvenile Myelomonocytic Leukemia (JMML). JMML is a rare form of chronic leukemia that affects young children, usually before the age of five. JMML results from DNA mutations in cells called monocytes. Normal monocytes attack invading microorganisms and assist lymphocytes in carrying out immune functions. Abnormal monocytes in JMML accumulate in the bone marrow and interfere with the production of normal white blood cells, red blood cells, and platelets.
If AML transformed from MDS or MPN (including JMML), check “yes” and complete both the AML and MDS/MPN disease classification sections (questions 122-170). If AML did not transform from MDS or MPS, check “no.”

If MDS/MPN is suspected, but not confirmed by documented laboratory or pathologic findings, or if there is documentation of MDS/MPN concurrent with AML, check “no.”

**Question 5: Was disease (AML) therapy related?**

Agents such as radiation or systemic therapy used to treat other diseases (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, or breast cancer) can damage the marrow and lead to a secondary malignancy such as AML. If the diagnosis of AML is therapy-related, check “yes.”

If the diagnosis of AML is not therapy-related, check “no.”

- If AML was preceded by therapy-related MDS, check “no.”
- If the recipient developed AML after an environmental exposure (e.g., exposure to benzene), check “no.”

If it is unknown whether or not the diagnosis of AML was therapy-related, check “unknown.”

**Question 6: Did the recipient have a predisposing condition?**

A predisposing condition is a condition that contributes to the susceptibility of developing leukemia. Therefore, diagnosis of the condition increases the likelihood that the recipient will develop leukemia. If the recipient has a documented history of a predisposing condition, check “yes” and continue with question 7. If there is no history of a predisposing condition or if predisposition is unknown, indicate “no” or “unknown” and continue with question 9.

**Questions 7-8: Specify condition:**

Bloom syndrome is an autosomal recessive genetic disorder characterized by excessive chromosome breakage and corresponding rearrangements, proportional dwarfism, and sun sensitivity. The chromosomal instability seen in Bloom syndrome is generally assumed to be responsible for these individuals’ predisposition to malignancy.

Down syndrome is also a chromosomal disorder (trisomy 21). It is characterized by an additional chromosome 21. Down syndrome patients exhibit a particular set of facial characteristics, growth deficiency, and cognitive impairment. Although Down syndrome patients have a reduced risk of developing many common malignancies, they have an increased risk of developing leukemia.
Fanconi anemia is a rare genetic blood disorder that prevents the body from producing a sufficient number of new blood cells to function properly. Abnormal blood cells may also be produced. These patients are short in stature, exhibit skeletal anomalies, and have an increased risk of developing solid tumors and leukemias.

Neurofibromatosis type 1, also known as von Recklinghausen disease, is an autosomal dominant genetic disorder characterized by mutation of chromosome 17 resulting in the inactivation of the $NF1$ gene. This results in abnormal growth and proliferation of neural crest cells. Patients with neurofibromatosis type 1 often have multiple neurofibromas (benign neural tumors), skeletal abnormalities, café au lait spots, Lisch nodules, freckling in the axilla or groin, and/or optic nerve glioma. Patients with biallelic inactivation of $NF1$ may have an increased risk of developing malignant neoplasms, including rhabdomyosarcoma, pheochromocytoma, and, in children, myelodysplastic syndrome and acute leukemia.

Indicate the recipient’s predisposing condition prior to the diagnosis of leukemia. If the condition was “other,” specify the condition in question 8.

**Question 9: Were cytogenetics tested (conventional or FISH)?**

Cytogenetic analysis is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient’s disease. Testing methods you may see include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see [Appendix C](#).

**Examples of AML Cytogenetic Findings Categorized by Prognosis**

<table>
<thead>
<tr>
<th>Favorable</th>
<th>Intermediate</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>$t(15;17)$</td>
<td>Normal</td>
<td>$\geq 3$ abnormalities</td>
</tr>
<tr>
<td>$t(8;21)$</td>
<td>$+8$</td>
<td>5- or 5q-</td>
</tr>
<tr>
<td>$\text{inv}(16)$ or $t(16;16)$</td>
<td>$t(9;11)$</td>
<td>7- or 7q-</td>
</tr>
<tr>
<td></td>
<td><em>All other abnormalities</em></td>
<td>$t(9;22)$</td>
</tr>
</tbody>
</table>

Indicate if cytogenetic studies were obtained at any time prior to the start of the preparative regimen.

If cytogenetic studies were obtained, check “yes” and continue with question 10.

If cytogenetic studies were not obtained or it is unknown if chromosome studies were performed, indicate “no” or “unknown” and continue with question 47.
**Question 10: Results of tests:**

If cytogenetic studies identified abnormalities (any karyotype other than 46XX or 46XY), indicate "abnormalities identified" and continue with question 11.

If cytogenetic studies yielded “no evaluable metaphases” or there were “no abnormalities” identified, continue with question 47.

**Questions 11-46: Specify cytogenetic abnormalities identified at any time prior to the start of the preparative regimen:**

If question 10 indicates that abnormalities were identified, each of questions 11-46 must be answered as “yes” or “no.” Do not leave any response blank. Indicate “yes” for each cytogenetic abnormality identified at any time prior to the start of the preparative regimen. Indicate “no” for all options not identified by cytogenetic assessment at any time prior to the start of the preparative regimen. For cases where AML has transformed from MDS, only report “yes” for cytogenetic abnormalities identified on or after the date of diagnosis for AML. If one or more abnormalities are best classified as “other abnormality,” specify in question 45-46.

If ≥ 3 cytogenetic abnormalities were identified at any time prior to the start of the preparative regimen, select “yes” for question 44 (complex, ≥ 3 distinct abnormalities) and specify the corresponding abnormalities in questions 11-46. If any of these abnormalities are not listed among 11-43, report “other abnormality,” and specify in questions 45-46. For example, if the karyotype included -7, +8, and -13, report “yes” for questions 12, 18, 44, and 45. Complete the remaining indicators as “no” and do not leave any response blank.

**Question 47: Were tests for molecular markers performed (e.g., PCR)?**

Molecular assessment involves testing blood or bone marrow for the presence of known molecular markers associated with the recipient’s disease. Molecular assessments are the most sensitive test for genetic abnormalities and involve amplifying regions of cellular DNA by polymerase chain reaction (PCR), typically using RNA to generate complementary DNA through reverse transcription (RT-PCR). The amplified DNA fragments are compared to a control, providing a method of quantifying log increase of genetic mutation transcripts. Each log increase is a 10-fold increase of gene transcript compared to control.

Indicate if molecular studies were obtained at any time prior to the start of the preparative regimen.

If molecular studies were obtained, check “yes” and continue with question 48.

If molecular studies were not obtained or it is not known if molecular studies were performed, indicate “no” or “unknown” and continue with question 57.
Questions 48-56: Specify molecular markers identified at any time prior to the start of the preparative regimen:

If question 47 indicates that tests for molecular markers were performed, then each of questions 48-56 must be answered as “positive,” “negative,” or “not done.” Do not leave any response blank. If tests identified a molecular marker other than those listed in questions 48-54, use question 55 to report it. If question 55 is answered “positive” or “negative,” specify the other molecular marker in question 56. Add an additional instance in the FormsNet application for questions 55-56 if more than one “other molecular marker” is identified.

Common Molecular Markers Associated with AML

<table>
<thead>
<tr>
<th>Molecular Abnormality</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEBPA</td>
<td>CEBPA, aka CCAAT/enhancer binding protein α, is a transcription factor required for the differentiation of granulocytes. Numerous CEBPA mutations have been identified in relation to AML, with the majority of patients displaying biallelic mutations ultimately resulting in the down regulation of gene activity. Decreased gene activity results in decreased differentiation potential for immature granulocytes. An estimated 7-15% of AML patients have CEBPA mutations and CEBPA mutations are generally found in M1 and M2 subtypes in conjunction with intermediate-risk cytogenetics. Studies show an association with more favorable outcomes. 1</td>
</tr>
<tr>
<td>FLT3-D835 point mutation</td>
<td>FLT3 encodes a receptor tyrosine kinase. The FLT3-D835 point mutation, aka FLT3-TKD, is an activating mutation impacting tyrosine-kinase domains. FLT3 mutations are found in up to 1/3 of all AML patients. The clinical significance of TKD activation remains unclear. FLT3-D385 mutations are often found in conjunction with other mutations. Overall, FLT3-D385 is not considered a favorable or poor prognostic indicator. However, in certain combinations with other mutations, there are associations with both improved and diminished survival. 23</td>
</tr>
<tr>
<td>FLT3-ITD mutation</td>
<td>FLT3 encodes a receptor tyrosine kinase. The FLT3-ITD (internal tandem duplication) interferes with certain down regulation functions within receptor tyrosine kinases, leading to activation of TK activity. FLT3 mutations are found in up to 1/3 of all AML patients. FLT3-ITD is considered a poor prognostic factor. Sorafenib (Nexavar) has been shown to initially improve disease response in FLT3-ITD-positive AML. 4</td>
</tr>
<tr>
<td>IDH1</td>
<td>Isocitrate Dehydrogenase (IDH) is an oxidative enzyme involved in the citric acid cycle. IDH1 mutations result in incorrect catalytic activity, leading to increased levels of an oncometabolite, 2-hydroxyglutarate. The pathologic activity of IDH1 mutations is still being studied, but it has been suggested that IDH mutations may be a distinct mechanism in AML pathogenesis; research models show they may cause an accumulation of hematopoietic progenitor cells. Early research suggests IDH1 mutation may be a less favorable prognostic indicator. 5</td>
</tr>
</tbody>
</table>
| IDH2                  | Isocitrate Dehydrogenase (IDH) is an oxidative enzyme involved in the citric acid cycle. IDH2 is a mitochondrial homolog to IDH1. Much like IDH1 mutations, IDH2 mutations result in incorrect catalytic activity, leading to increased levels of (D)-2-hydroxyglutarate. The pathologic activity of IDH2 mutations are still being studied, but it has been suggested that IDH mutations may be a distinct mechanism in AML pathogenesis; research models show they may cause an accumulation of hematopoietic progenitor cells. Early research suggests IDH2 mutation may be
A more favorable prognostic indicator, unlike IDH1 mutation, though there may be differences based on where the IDH2 mutation occurs in gene.  

| KIT | KIT encodes a receptor tyrosine kinase. The KIT mutations at exons 8 and 17 are associated with activation of encoded proteins, resulting in activation impacting tyrosine-kinase domains. Patients with t(8;21) and inv(16) cytogenetics are frequently screened for KIT mutations, which adversely affect prognosis in these patients.  

| NPM1 | NPM1 encodes a protein responsible for multiple cellular functions, including the regulation of the ARF-p53 tumor suppressor pathway. Mutations in NPM1 result in gene over-expression and subsequent inactivation of ARF-p53 tumor suppression pathway. NPM1 mutations are one of the most common molecular markers seen in AML and are associated with improved survival.  

| Other molecular marker | Assessments for other molecular markers known or believed to be associated with AML may be performed. If these studies are performed, indicate “positive” or “negative” and specify the marker in question.  

---


Question 57: What was the disease status (based on hematologic test results)?

Indicate the disease status of AML at the last assessment prior to the start of the preparative regimen. Refer to the AML Response Criteria section of the forms instructions manual for definitions of each response.

Question 58: How many cycles of induction therapy were required to achieve CR?

Chemotherapy is initially given as induction therapy intended to bring the disease into remission. Recipients usually have one to two cycles of induction therapy; disease prognosis is considered less favorable if the patient fails to achieve remission with the first induction therapy and even poorer if patients fail two or more induction therapies. An example of a common induction therapy for all AML subtypes (except M3) is a combination of an anthracycline and cytarabine, commonly known as "7+3." In this regimen, cytarabine is typically administered for seven days at a dose of 100 mg/m^2/day. The anthracycline (usually daunorubicin at 45 to 60 mg/m^2/day or idarubicin at 12 mg/m^2/day) is generally given on the first three days the cytarabine is given.

The second phase of chemotherapy is known as consolidation therapy. The goal of consolidation therapy is to destroy any remaining leukemia cells and sustain remission. An example of a common consolidation therapy for all AML subtypes (except M3) is high-dose cytarabine, commonly referred to as “HiDAC.” In this regimen, cytarabine is typically administered at a dose exceeding 10 g/m^2 per cycle.

Maintenance chemotherapy may follow consolidation therapy. Maintenance chemotherapy is given in lower doses and is intended to prolong a remission. Maintenance therapy is used less commonly for the treatment of AML than other malignancies. Treatment may also be administered for relapsed disease. Much like induction therapy, treatment for relapse is intended to bring the disease back into remission. Systemic therapeutic agents used to induce remission following relapse often differ from those used in the initial induction, since the disease is often resistant to many of the agents used earlier in the disease course and is considered high-risk with a poor prognosis. Allogeneic HCT is often considered the only potential “cure” for relapsed disease.

Indicate the number of cycles of induction therapy that were required to achieve the first CR.

**Question 59: Was the recipient in molecular remission?**

Molecular assessment involves testing blood or bone marrow for the presence of known molecular markers associated with the recipient’s disease. Molecular assessments are the most sensitive test for genetic abnormalities and involve amplifying regions of cellular DNA by polymerase chain reaction (PCR), typically using RNA to generate complementary DNA through reverse transcription (RT-PCR).

Molecular remission is a treatment response in which no minimal residual disease in the blood and/or marrow can be detected by molecular methods (e.g., PCR).

If molecular abnormalities associated with the recipient’s disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”

If molecular abnormalities associated with the recipient’s disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”

Indicate “unknown” if molecular abnormalities associated with the recipient’s disease were identified previously and no molecular assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No molecular assessments were performed at any time prior to the start of the preparative regimen.
- Molecular abnormalities associated with the recipient’s disease were not identified on previous testing and no molecular abnormalities were identified at the last evaluation prior to the start of the preparative regimen.

**Question 60: Was the recipient in remission by flow cytometry?**

Flow cytometry assessment is a method of analyzing peripheral blood, bone marrow, or tissue preparations for multiple unique cell characteristics. Its primary clinical purpose in the setting of leukemias is to quantify blasts in the peripheral blood or bone marrow, or to identify unique cell populations through immunophenotyping. Flow cytometry assessment may also be referred to as “MRD,” or minimal residual disease, testing.

Flow cytometric remission is a treatment response in which no blasts can be detected.

If flow cytometric abnormalities associated with the recipient’s disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”
If flow cytometric abnormalities associated with the recipient’s disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”

Indicate “unknown” if flow cytometric abnormalities associated with the recipient’s disease were identified previously and no flow cytometry assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No flow cytometry assessments were performed at any time prior to the start of the preparative regimen.
- Flow cytometric abnormalities were not identified on previous testing and no flow cytometric abnormalities were identified at the last evaluation prior to the start of the preparative regimen.

**Question 61: Was the recipient in cytogenetic remission?**

Cytogenetic assessment involves testing blood or bone marrow for the presence of a known cytogenetic abnormalities that reflect the recipient’s disease. FISH is categorized with cytogenetics. Although often used for finding specific features in DNA, FISH is not as sensitive as molecular methods, even though the markers identified may be the same.

Cytogenetic remission is a treatment response where **both** of the following criteria are met:

- The karyotype reverts to normal, and
- There are no clonal chromosomal abnormalities detected in the blood and/or marrow.

If cytogenetic abnormalities associated with the recipient's disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”

If cytogenetic abnormalities associated with the recipient's disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”

Indicate “unknown” if cytogenetic abnormalities associated with the recipient’s disease were identified previously and no cytogenetic assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No cytogenetic assessments were performed at any time prior to the start of the preparative regimen.
- Cytogenetic abnormalities were not identified on previous testing and no cytogenetic abnormalities were identified at the last evaluation prior to the start of the preparative regimen.
Continue with question 62.

**Question 62: Date of most recent relapse:**

Enter the date of the most recent relapse prior to the start of the preparative regimen. If reporting a pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear), enter the date the sample was collected. If extramedullary disease was detected by radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), enter the date the imaging took place. If the physician determines cytogenetic or molecular relapse, enter the date the sample was collected for cytogenetic or molecular evaluation. If the physician determines evidence of relapse following a clinical assessment during an office visit, report the date of assessment.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

**Question 63: Date assessed**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the white blood cells. It is characterized by the rapid proliferation of abnormal, immature lymphocytes, known as lymphoblasts, in the bone marrow. This accumulation of blasts in the marrow prevents the formation of healthy red blood cells, white blood cells and/or platelets. Normal lymphoblasts develop into B and T lymphocytes that fight infection. In ALL, the leukemic lymphoblasts do not fully develop and therefore cannot fight infection. The symptoms of ALL are caused by the replacement of normal bone marrow with leukemic cells, resulting in a drop in red blood cells, platelets, and normal white blood cells. It is estimated that 80-85% of ALL cases occur in children, with peak incidence of pediatric ALL at age 5. Biologically, adult and pediatric ALL are very different. Pediatric cases are more often characterized by favorable prognostic indicators including a precursor B-cell population, TEL/AML1 fusion gene, and/or hyperdiploidy; adult cases are more often characterized by poor prognostic indicators including a precursor T-cell population and/or BCR/ABL fusion gene.\(^1\)


**Question 64: Specify ALL classification**

Indicate the disease classification at diagnosis.

Due to the aggressive nature of precursor T- and precursor B-cell lymphoblastic lymphoma (or lymphoma/leukemia), the primary disease reported for recipients with these malignancies should be acute lymphoblastic leukemia (T-cell lymphoblastic leukemia/lymphoma or B-cell ALL, NOS (L1/L2)).

If the cytogenetic or molecular abnormalities present at diagnosis are listed on the Pre-TED form, check the sub-type rather than “B-cell ALL, NOS” option.

**Question 65: Were tyrosine kinase inhibitors (i.e., imatinib mesylate) given for pre-HCT therapy at any time prior to the start of the preparative regimen?**

Imatinib mesylate is also known as Gleevec, Glivec, STI-571, or CGP57148B. Indicate “yes” or “no.”

**Question 66: Were cytogenetics tested (conventional or FISH)?**

Cytogenetic analysis is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient’s disease. Testing methods include conventional chromosome analysis (karyotyping) or fluorescence \textit{in situ} hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C.
Examples of ALL Cytogenetic Findings Categorized by Prognosis (Adult Precursor B-cell ALL)²

<table>
<thead>
<tr>
<th>Favorable</th>
<th>Intermediate</th>
<th>Poor</th>
<th>Very Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>High hyperdiploidy (51-65 chromosomes)</td>
<td>Normal</td>
<td>-7/del(7p)</td>
<td>≥ 5 abnormalities</td>
</tr>
<tr>
<td></td>
<td>11q abnormalities</td>
<td>+8</td>
<td>t(4;11)</td>
</tr>
<tr>
<td></td>
<td>del(6q)</td>
<td>11q23 abnormalities/MLL</td>
<td>t(8;14)</td>
</tr>
<tr>
<td></td>
<td>del(17p)</td>
<td>t(1;19)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>del(9p)</td>
<td>t(17;19)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>del(12p)</td>
<td>t(5;14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-13/del(13q)</td>
<td>t(9;22)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(14q32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>t(10;14)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low hyperdiploidy (47-50 chromosomes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tetraploidy (&gt; 80 chromosomes)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Indicate if cytogenetic studies were obtained at any time prior to the start of the preparative regimen.

If cytogenetic studies were obtained, check “yes” and continue with question 67.

If cytogenetic studies were not obtained, or if it is unknown if chromosome studies were performed, indicate “no” or “unknown” and continue with question 95.

**Question 67: Results of test**

If cytogenetic studies identified abnormalities (any karyotype other than 46XX or 46XY), indicate “abnormalities identified” and continued with question 68.

If cytogenetic studies yielded “no evaluable metaphases” or there were “no abnormalities” identified, continue with question 95.

**Questions 68-94: Specify abnormalities**

If question 67 indicates that abnormalities were identified, each of questions 68-94 must be answered as “yes” or “no.” Do not leave any response blank. Indicate “yes” for each cytogenetic abnormality identified at any time prior to the start of the preparative regimen in questions 68-93; indicate “no” for all options not identified on cytogenetic assessment at any time prior to the start of the preparative regimen. If one or more abnormalities are best classified as “other abnormality,” specify in question 94.
If ≥ 3 cytogenetic abnormalities are identified at any time prior to the start of the preparative regimen, select “yes” for question 92 (complex, ≥ 3 distinct abnormalities) and specify the corresponding abnormalities in questions 68-92. If any of these abnormalities are not listed among 68-92, report “other abnormality,” and specify in question 93. For example, if the karyotype included -7, +8, and -13, report “yes” for questions 68, 70, 92, and 93-94. Answer the remaining questions “no” and do not leave any response blank.

**Question 95: Were tests for molecular markers performed (e.g., PCR)?**

Molecular assessment involves testing blood or bone marrow for the presence of known molecular markers associated with the recipient’s disease. Molecular assessments are the most sensitive test for genetic abnormalities and involve amplifying regions of cellular DNA by polymerase chain reaction (PCR), typically using RNA to generate complementary DNA through reverse transcription (RT-PCR). The amplified DNA fragments are compared to a control, providing a method of quantifying log increase of genetic mutation transcripts. Each log increase is a 10-fold increase of gene transcript compared to control.

Indicate if molecular studies were obtained at any time prior to the start of the preparative regimen.

If molecular studies were obtained, check “yes” and continue with question 96.

If molecular studies were not obtained or it is not known if molecular studies were performed, indicate “no” or “unknown” and continue with question 100.

**Questions 96-99: Specify abnormalities**

If question 95 indicates that tests for molecular markers were performed, then each of questions 96-98 must be answered as “positive,” “negative,” or “not done.” Do not leave any response blank. If question 98 is answered “positive” or “negative,” specify the molecular marker identified in question 99. If more than one “other molecular marker” is identified, add an additional instance in the FormsNet application for questions 98-99.

**Common Molecular Markers Associated with ALL**

<table>
<thead>
<tr>
<th>Molecular Abnormality</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCR-ABL</td>
<td>BCR-ABL, aka Philadelphia chromosome, refers to the tyrosine kinase gene fusion resulting from the translocation of material from chromosome 9 (ABL) onto chromosome 22 (BCR). Molecular weight varies depending on exact location of the translocation; isoform p190 is typically seen in ALL. Tyrosine kinase inhibitor therapies such as imatinib mesylate (Gleevec) target and block ABL from fusing with BCR. Presence of BCR-ABL gene fusion is associated with poorer outcomes.</td>
</tr>
</tbody>
</table>
TEL-AML1

TEL-AML1, aka ETV6-RUNX1, is a fusion gene resulting from the translocation of chromosomes 12 and 21. It is the most common fusion gene seen in childhood precursor B-cell ALL. Research in murine models shows that cell lines expressing TEL-AML1 proliferate more slowly than the non-expressing cell lines, but evade inhibition of proliferation typically regulated by tissue growth factor β (TGF-β), ultimately leading to the growth of the leukemic cell population. TEL-AML1 is considered a favorable prognostic indicator.\(^4\)

Other molecular marker

Assessments for other molecular markers known or believed to be associated with ALL may be performed. If these studies were performed, indicate “positive” or “negative” and specify the marker in question 99.

---


**Question 100: What was the disease status (based on hematological test results)?**

Indicate the disease status of ALL at the last assessment prior to the start of the preparative regimen. Refer to the **ALL Response Criteria** section of the Forms Instructions Manual for definitions of each response.

**Question 101: How many cycles of induction therapy were required to achieve CR?**

Chemotherapy is initially given as induction therapy intended to bring the disease into remission. Recipients usually have one to two cycles of induction therapy. An example of a common induction therapy for precursor B-cell ALL in children with higher-risk prognostic indicators is a combination of vincristine, prednisone, an anthracycline, and L-asparaginase given over 4-6 weeks. Patients with a rapid response, defined as < 5% blasts within 7 to 14 days of starting induction, have improved outcomes.\(^6\)

The second phase of chemotherapy is known as consolidation therapy. The goal of consolidation therapy is to destroy any remaining leukemia cells and sustain remission. An example of a consolidation therapy for precursor B-cell ALL in children is daunorubicin and cytarabine; several studies support the use of consolidation therapy in ALL.

Maintenance therapy typically involves daily doses of mercaptopurine and weekly doses of methotrexate. Treatment continues for 2-3 years for most children with ALL. Treatment may also be administered for relapsed disease. Much like induction therapy, treatment for relapse is intended to bring the disease back
into remission. Systemic therapeutic agents used to induce remission following relapse often differ from those used during initial induction, since the disease is considered high-risk with a poor prognosis and is often resistant to many of the agents used earlier in the disease course. Allogeneic HCT is often considered the only potential “cure” for relapsed disease, if the patient has not already been transplanted.

Indicate the number of cycles of induction therapy that were required to achieve the first CR.


Question 102: Was the recipient in molecular remission?

Molecular assessment involves testing blood or bone marrow for the presence of known molecular markers associated with the recipient’s disease. Molecular assessments are the most sensitive test for genetic abnormalities and involve amplifying regions of cellular DNA by polymerase chain reaction (PCR), typically using RNA to generate complementary DNA through reverse transcription (RT-PCR).

Molecular remission is a treatment response in which no minimal residual disease in the blood and/or marrow can be detected by molecular methods (e.g., PCR).

If molecular abnormalities associated with the recipient’s disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”

If molecular abnormalities associated with the recipient’s disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”

Indicate “unknown” if molecular abnormalities associated with the recipient's disease were identified previously and no molecular assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No molecular assessments were performed at any time prior to the start of the preparative regimen.
- Molecular abnormalities were not identified on previous testing and no molecular abnormalities were identified at the last evaluation prior to the start of the preparative regimen.

Question 103: Was the recipient in remission by flow cytometry?

Flow cytometry assessment is a method of analyzing peripheral blood, bone marrow, or tissue preparations for multiple unique cell characteristics. Its primary clinical purpose in the setting of leukemias is to quantify blasts in the peripheral blood or bone marrow, or to identify unique cell populations through
immunophenotyping. Flow cytometry assessment may also be referred to as “MRD,” or minimal residual disease, testing.

Flow cytometric remission is a treatment response in which no blasts can be detected.

If flow cytometric abnormalities associated with the recipient's disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”

If flow cytometric abnormalities associated with the recipient’s disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”

Indicate “unknown” if flow cytometric abnormalities associated with the recipient’s disease were identified previously and no flow cytometry assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No flow cytometry assessments were performed at any time prior to the start of the preparative regimen.
- Flow cytometric abnormalities were not identified on previous testing and no flow cytometric abnormalities were identified at the last evaluation prior to the start of the preparative regimen.

**Question 104: Was the recipient in cytogenetic remission?**

Cytogenetic assessment involves testing blood or bone marrow for the presence of known cytogenetic abnormalities that reflect the recipient’s disease. FISH is categorized with cytogenetics. Although often used for finding specific features in DNA, FISH is not as sensitive as molecular methods, even though the markers identified may be the same.

Cytogenetic remission is a treatment response where **both** of the following criteria are met:

- The karyotype reverts to normal, and
- There are no clonal chromosomal abnormalities detected in the blood and/or marrow.

If cytogenetic abnormalities associated with the recipient's disease were identified previously, but the criteria above were met at the last evaluation prior to the start of the preparative regimen, indicate “yes.”

If cytogenetic abnormalities associated with the recipient’s disease were identified at the last evaluation prior to the start of the preparative regimen, indicate “no.”
Indicate “unknown” if cytogenetic abnormalities associated with the recipient’s disease were identified previously and no cytogenetic assessment was performed prior to the start of the preparative regimen.

Indicate “not applicable” if one of the following applies:

- No cytogenetic assessments were performed at any time prior to the start of the preparative regimen.
- Cytogenetic abnormalities were not identified on previous testing and no cytogenetic abnormalities were identified at the last evaluation prior to the start of the preparative regimen.

Continue with question 106.

**Question 105: Date of most recent relapse:**

Enter the date of the most recent relapse prior to the start of the preparative regimen. If reporting a pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear), enter the date the sample was collected. If extramedullary disease was detected by radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), enter the date the imaging took place. If the physician determines cytogenetic or molecular relapse, enter the date the sample was collected for cytogenetic or molecular evaluation. If the physician determines evidence of relapse following a clinical assessment during an office visit, report the date of assessment.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

**Question 461: Date assessed**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
Q107-110: Acute Leukemias of Ambiguous Lineage and Other Myeloid Neoplasms

Questions 107-108: Specify other acute leukemia classification

Indicate the other acute leukemia disease classification at diagnosis. If the subtype is not listed, report as “other leukemia” and specify the reported disease.

- Acute undifferentiated leukemia is a type of AML characterized by immature predominating cells that cannot be classified.
- Biphenotypic, bilineage, or hybrid leukemias have characteristics representative of both myeloid and lymphoid lineages.
- Mast cell leukemia is characterized by an increased number of tissue mast cells in the peripheral blood.

Question 109: What was the disease status (based on hematological test results)?

Indicate the disease status of acute leukemia at the last evaluation prior to the start of the preparative regimen.

**Primary Induction Failure (PIF)**

The patient received treatment for acute leukemia but never achieved complete remission at any time. PIF is not limited by the number of unsuccessful treatments; this disease status only applies to recipients who have never been in complete remission.

**Complete Remission (CR)**

Hematologic complete remission is defined as meeting all of the following response criteria for at least four weeks.

- < 5% blasts in the bone marrow
- Normal maturation of all cellular components in the bone marrow
- No extramedullary disease (e.g., CNS, soft tissue disease)
- Neutrophils ≥ 1,000/µL
- Platelets ≥ 100,000/µL
- Transfusion independent
In some cases, there may not be a four-week interval between completion of therapy and the pre-transplant disease assessment; in this case, CR should still be reported as the status at transplant, since it represents the “best assessment” prior to HCT. This is an exception to the criteria that CR be durable beyond four weeks; the pre-transplant disease status should not be changed based on early relapse or disease assessment post-transplant.

Include recipients with persistent cytogenetic or molecular abnormalities who meet the above CR criteria for hematologic CR.

Include recipients meeting the above CR criteria regardless of how many courses of therapy were required to achieve CR.

The number of this complete remission can be determined by using the following guidelines:

- 1st CR: no prior relapse
- 2nd CR: one prior relapse
- 3rd or higher: two or more prior relapses

**Relapse (REL)**

Relapse is defined as the recurrence of disease after CR, meeting the following criteria:

- ≥ 5% blasts in the marrow or peripheral blood
- Extramedullary disease
- Reappearance of cytogenetic and/or molecular abnormalities associated with diagnosis that, in the judgment of a physician, are at a level representing relapse
- Disease presence determined by a physician upon clinical assessment

The number of this relapse can be determined by using the following guidelines:

- 1st relapse: one prior CR
- 2nd relapse: two prior CRs
- 3rd or higher: three or more CRs

Do not include a partial response (PR) when determining number of relapse. Recipients who achieve a PR to treatment should be classified as either PIF or relapse; PR in acute leukemia is generally of short duration and is unlikely to predict clinical benefit.
No Treatment
The recipient was diagnosed with acute leukemia and never received therapeutic agents; include patients who have received only supportive therapy, including growth factors and/or blood transfusions.

Question 110: Date assessed
Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
**Q111-121: Chronic Myelogenous Leukemia**

Chronic myelogenous leukemia (CML) is a slow-progressing cancer of the myeloid white blood cells. It is characterized by increased proliferation of immature white blood cells (granulocytes) with damaged DNA, or blasts, which accumulate in the blood and bone marrow. Normal blasts develop into white blood cells that fight infection. The symptoms of CML are caused by the replacement of normal bone marrow with leukemic cells, resulting in fewer red blood cells, platelets, and normal white blood cells.

**Question 111: Was therapy given prior to this HCT?**

If the recipient received therapy to treat CML prior to this HCT, check “yes” and go to question 112. Do not report a prior HCT or cellular therapy as these are captured separately on the Pre-TED Form (Form 2400). If the recipient did **not** receive therapy to treat CML, check “no” and go to question 118.

**Questions 112-117: CML treatment**

Indicate the therapy the recipient received to treat CML prior to this HCT. If the recipient's treatment consisted of a combination of chemotherapeutic agents, check the “combination chemotherapy” box and each drug included in the combination from the list provided. The “other, specify” category should only be used if the drug is not one of the listed options. For example, if the recipient received a combination of interferon and cytarabine, check all of the following: “combination chemotherapy,” “interferon,” and “other, specify: cytarabine.”

**Question 118: What was the disease status at last evaluation prior to the start of the preparative regimen?**

Indicate the disease status of CML at the last evaluation prior to the start of the preparative regimen (or infusion if no preparative regimen was given). Refer to the CML Response Criteria section for a description of each disease response.

If the recipient is in complete hematologic response or chronic phase at the start of the preparative regimen, go to question 119. Otherwise, go to question 120.

**Question 119: Specify level of response**

If the recipient's disease status (question 118) is “complete hematologic remission” or “chronic phase,” specify the cytogenetic / molecular response. Refer to the below definitions of cytogenetic and molecular responses.

**Definitions of Cytogenetic and Molecular Responses to Therapy**
<table>
<thead>
<tr>
<th>Response</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete molecular remission</td>
<td>0% BCR / ABL transcripts detected in peripheral blood or bone marrow</td>
</tr>
<tr>
<td>(most favorable)</td>
<td></td>
</tr>
<tr>
<td>Major molecular remission</td>
<td>&gt; 0 – 0.1% BCR / ABL transcripts detected in peripheral blood or bone</td>
</tr>
<tr>
<td>response</td>
<td>marrow</td>
</tr>
<tr>
<td>Complete cytogenetic response</td>
<td>0% Ph+ cells detected in bone marrow</td>
</tr>
<tr>
<td>Partial cytogenetic response</td>
<td>&gt; 0 – 35% Ph+ cells in bone marrow</td>
</tr>
<tr>
<td>Minor cytogenetic response</td>
<td>&gt; 35 – 65% Ph+ cells in bone marrow</td>
</tr>
<tr>
<td>Minimal cytogenetic response</td>
<td>&gt; 65 – 95% Ph+ cells in bone marrow</td>
</tr>
<tr>
<td>No cytogenetic response</td>
<td>&gt; 95% Ph+ cells in bone marrow.</td>
</tr>
<tr>
<td>(least favorable)</td>
<td></td>
</tr>
</tbody>
</table>


The above responses are listed from most favorable (complete molecular remission) to least favorable (no cytogenetic response). Centers should report the most favorable response achieved. For example, if a recipient has achieved a major molecular remission by PCR testing as well as a complete cytogenetic response by karyotyping / FISH, the center should report “major molecular remission” for question 119.

**Question 120: Number**

Indicate the number of the disease phase reported in question 118.

**Question 121: Date assessed**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia (abnormal growth or development leading to an alteration in size, shape, and organization of the cell) in one or more of the major myeloid cell lines (WBC, RBC, and/or platelets), ineffective hematopoiesis, and an increased risk of developing acute myelogenous leukemia (AML). MDS occurs primarily in older adults, with a median age of 70 years. The majority of patients present with symptoms related to cytopenias. Most patients present with anemia requiring RBC transfusions.

Primary or de novo MDS occurs without a known history of chemotherapy or radiation exposure. Some inherited hematologic disorders, such as Fanconi anemia, dyskeratosis congenita, Shwachmann-Diamond syndrome, and Diamond-Blackfan syndrome are associated with an increased risk of MDS.

Myeloproliferative Neoplasms (MPN) are characterized by the overproduction of blood cells (red blood cells, white blood cells, and/or platelets) or collagen in the bone marrow. Often the MPN will be identified because of a blood test for another condition, as some patients are asymptomatic. Common symptoms found in the array of myeloproliferative disorders include fatigue and the enlargement of the spleen (splenomegaly).

**Question 122: What was the MDS/MPN subtype?**

Please indicate the MDS/MPN subtype at diagnosis. For a list of MDS/MPN subtypes and their diagnostic criteria, see Appendix H.
If the MDS/MPN subtype at diagnosis was “atypical chronic myeloid leukemia,” continue with question 220.

**Question 123: Was the disease (MDS/MPN) therapy-related?**

Agents such as radiation or systemic therapy used to treat other diseases (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, or breast cancer) can damage the marrow and lead to a secondary malignancy, such as MDS/MPN. If the diagnosis of MDS/MPN is therapy-related, select “yes.” If the diagnosis of MDS/MPN is not therapy-related, select “no.” If it is unknown if the MDS/MPN is therapy-related, select “unknown.”

Do not answer this question “yes” if the recipient developed MDS/MPN after an environmental exposure (e.g., exposure to benzene).

**Question 124: Did the recipient have a predisposing condition?**

A predisposing condition is a condition that contributes to the susceptibility of developing MDS/MPN. If the recipient has a documented history of a predisposing condition, select “yes” and continue with question 125. If there is no history of a predisposing condition or if predisposition is unknown, indicate “no” or “unknown” and continue with question 127.

**Questions 125-126: Specify condition:**

Aplastic anemia may progress to MDS and/or AML. Aplastic anemia is a broad classification referring to bone marrow failure characterized by pancytopenia and marrow hypoplasia.

Bloom syndrome is an autosomal recessive genetic disorder characterized by excessive chromosome breakage, with corresponding rearrangements. It is characterized by proportional dwarfism and sun sensitivity. The chromosomal instability seen in Bloom syndrome is generally assumed to be responsible for these individuals' predisposition to malignancy.

Down syndrome is also a chromosomal disorder. It is characterized by an additional chromosome 21, also referred to as trisomy 21. Down syndrome patients exhibit a particular set of facial characteristics, growth deficiency, and cognitive impairment. Although Down syndrome patients have a reduced risk of developing many common malignancies, they have an increased risk of developing leukemia.

Fanconi anemia is a rare genetic blood disorder that prevents the body from producing a sufficient number of new blood cells to function properly. Abnormal blood cells may also be produced. These patients are short in stature, exhibit skeletal anomalies, and have an increased risk of developing solid tumors and leukemias.

If the recipient had a predisposing condition not listed above, select “other condition” and specify the condition in question 126.
Questions 127-128: WBC

Indicate whether the white blood cell (WBC) count was “known” or “unknown” at diagnosis. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 128. If “unknown,” continue with question 129.

Questions 129-130: Hemoglobin

Indicate whether the hemoglobin was “known” or “unknown” at diagnosis. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 130. If “unknown,” continue with question 132.

Question 131: Were RBCs transfused ≤ 30 days before the date of test?

Transfusions temporarily increase the red blood cell count. It is important to distinguish between a recipient whose body is creating these cells and a recipient who requires transfusions to support the counts.

Indicate if red blood cells were transfused less than or equal to 30 days prior to the testing reported in question 130.

Questions 132-133: Platelets

Indicate whether the platelet count was “known” or “unknown” at diagnosis. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 133. If “unknown,” continue with question 135.

Question 134: Were platelets transfused ≤ 7 days before date of test?

Transfusions temporarily increase the platelet count. It is important to distinguish between a recipient whose body is creating the platelets and a recipient who requires transfusions to support the counts.

Indicate if platelets were transfused less than or equal to 7 days prior to the testing reported in question 133.

Questions 135-136: Neutrophils

Indicate whether the neutrophil percentage in the blood was “known” or “unknown” at diagnosis. If “known,” report the value documented on the laboratory report in question 136. If “unknown,” continue with question 137.
Questions 137-138: Blasts in bone marrow

If the bone marrow pathology report states a range for blasts, enter the average of the range rounded to the nearest whole number (e.g., if 0-5%, enter 3%). If the report indicates “sheets of blasts” or “packed marrow,” report 100%. If the report states > n% blasts, enter (n +1)% on the form. For example, if the laboratory report indicates > 90% blasts, report 91%. If the report states < n% blasts, enter (n -1)% on the form. For example, if the laboratory report indicates < 5% blasts, report 4%.

Indicate whether the percentage of blasts in the bone marrow was “known” or “unknown” at diagnosis. If “known,” report the percentage documented on the laboratory report in question 138. If “unknown,” continue with question 139.

Question 139: Were cytogenetics tested (conventional or FISH)?

Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient’s disease. Testing methods you may see include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C.

Indicate if cytogenetic studies were obtained at diagnosis. If cytogenetic studies were obtained, select “yes” and continue with question 140.

If no cytogenetic studies were obtained or it is unknown if chromosome studies were performed, select “no” or “unknown” and continue with question 167.

Question 140: Results of test:

If cytogenetic studies identified abnormalities, indicate “abnormalities identified” and continue with question 141.

If cytogenetic studies yielded “no evaluable metaphases” or there were “no abnormalities” identified, continue with question 167.

Question 141: Specify the number of distinct cytogenetic abnormalities:

Indicate the total number of abnormalities at diagnosis.
Questions 142-166: Specify abnormalities identified at diagnosis:

Report all abnormalities identified by all methods of cytogenetic assessment at diagnosis by selecting “yes” or “no” for each question. Do not leave any response blank. If one or more abnormalities are best classified as “other abnormality,” select “yes” for question 165 and specify the abnormality in question 166.

Question 167: Did the recipient progress or transform to a different MDS/MPN subtype between diagnosis and the start of the preparative regimen?

**Transformation to Myelofibrosis**

Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. However, effective immediately, cases of post-essential thrombocythemia myelofibrosis (post-ET MF) or post-polycythemia vera myelofibrosis (post-PV MF) will now be reported as “Primary Myelofibrosis (PMF)” at the time of HCT. In order to capture accurate data, the secondary MF cases need to be lumped in with the PMF cases, since treatment for post-ET MF and post-PV MF is the same as PMF.

Indicate if the recipient's disease progressed to AML or transformed into a different MDS/MPN subtype between initial diagnosis and the start of the preparative regimen. Approximately one third of MDS cases transform into AML, signifying a poorer prognosis. Progression to AML is defined by an increase in blood or bone marrow blasts equal to or greater than 20%.

MDS/MPN subtypes may also transform/progress from one into another. A progression from one subtype of MDS to another indicates that the number of cytopenias, number of blasts, and/or morphology of marrow sufficiently qualified them for a higher grade (i.e., more severe) MDS. For example, an MDS classified as RCUD at diagnosis whose blast count rises to 8% as documented on bone marrow aspirate would have progressed to RAEB-1.

Conversely, do not report a progression/transformation if the recipient's assessments after diagnosis show that they qualify for a lower grade (i.e., less severe MDS). For example, a recipient who is diagnosed with RAEB-2, but whose assessments show that they meet the criteria for RAEB-1 as a response to treatment, would not qualify as a progression or transformation. In this example, the disease is lower grade (i.e., less severe), rather than a higher grade (i.e., more severe) so it should not be reported as a progression/transformation. See the table below for guidance in determining the severity of MDS/MPN progressions and transformations.

**Grade of MDS Progression/Transformations**
Indicate if the recipient’s disease progressed to AML or transformed from one MDS/MPN subtype to another. If the recipient’s disease did transform or progress, select “yes” and continue with question 168. If there was no documented transformation or progression, select “no” and continue with question 171.

If there was no documented transformation or progression and the disease subtype is JMML, continue to the signature line.

**Question 168: Specify the MDS/MPN subtype after transformation:**

Indicate the recipient’s current MDS/MPN subtype after transformation. If the recipient experienced more than one transformation after diagnosis, report the most recent subtype. For a list of MDS/MPN subtypes and their diagnostic criteria, see Appendix H.

Unless the recipient transformed to AML, continue with question 169.

If the disease transformed to AML, go to question 170.

**Question 169: Specify the date of the most recent transformation:**

Report the date of assessment that determined the *most recent* disease transformation (i.e., if there were multiple transformations, report the most recent). Report the date of the pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear). Enter the date the sample was collected for pathological and laboratory evaluations.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

**Question 170: Date of MDS Diagnosis**

If the recipient’s MDS / MPN transformed to AML prior to HCT, report the date of diagnosis of MDS / MPN.
in question 170. If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

Ensure the date of diagnosis for AML has been reported in question 1, AML is reported as the primary disease for HCT in question 2, and the AML section of the Pre-TED Disease Classification Form has been complete appropriately. Go to the signature line.

Questions 171-172: WBC

Indicate whether the white blood cell (WBC) count was “known” or “unknown” at the last evaluation prior to the start of the preparative regimen. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 172. If “unknown,” continue with question 173.

Questions 173-174: Hemoglobin

Indicate whether the hemoglobin was “known” or “unknown” at the last evaluation prior to the start of the preparative regimen. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 174. If “unknown,” continue with question 176.

Question 175: Was RBCs transfused < 30 days before the date of test?

Transfusions temporarily increase the red blood cell count. It is important to distinguish between a recipient whose body is creating these cells and a recipient who requires transfusions to support the counts.

Indicate if red blood cells were transfused less than or equal to 30 days prior to the testing reported in question 174.

Questions 176-177: Platelets

Indicate whether the platelet count was “known” or “unknown” at the last evaluation prior to the start of the preparative regimen. If “known,” report the laboratory count and unit of measure documented on the laboratory report in question 177. If “unknown,” continue with question 179.

Question 178: Were platelets transfused < 7 days before date of test?

Transfusions temporarily increase the platelet count. It is important to distinguish between a recipient whose body is creating the platelets and a recipient who requires transfusions to support the counts.

Indicate if platelets were transfused less than or equal to 7 days prior to the testing reported in question 177.
Questions 179-180: Neutrophils

Indicate whether the neutrophil percentage in the blood was “known” or “unknown” at the last evaluation prior to the start of the preparative regimen. If “known,” report the value documented on the laboratory report in question 180. If “unknown,” continue with question 181.

Questions 181-182: Blasts in bone marrow:

If the bone marrow pathology report states a range for blasts, enter the average of the range rounded to the nearest whole number (e.g., if 0-5%, enter 3%).
If the report indicates “sheets of blasts” or “packed marrow,” report 100%.
If the report states > n% blasts, enter (n+1)% on the form. For example, if the laboratory report indicates > 90% blasts, report 91%.
If the report states < n% blasts, enter (n-1)% on the form. For example, if the laboratory report indicates < 5% blasts, report 4%.

Questions 183: Were cytogenetics tested (conventional or FISH)?

Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient’s disease. Testing methods you may see include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix.

Indicate if cytogenetic studies were obtained at the last evaluation prior to the start of the preparative regimen. If cytogenetic studies were obtained, select “yes” and continue with question 184.

If no cytogenetic studies were obtained or it is unknown if chromosome studies were performed, select “no” or “unknown” and continue with question 211.

Question 184: Results of test:

If cytogenetic studies identified abnormalities, indicate “abnormalities identified” and continue with question 185.

If cytogenetic studies yielded “no evaluable metaphases” or there were “no abnormalities” identified, continue with question 211.
**Question 185: Specify the number of distinct cytogenetic abnormalities:**

Indicate the total number of abnormalities at the last evaluation prior to the start of the preparative regimen.

**Questions 186-210: Specify abnormalities identified at the last evaluation prior to the start of the preparative regimen:**

Report all abnormalities identified by all methods of cytogenetic assessment at the last evaluation prior to the start of the preparative regimen by selecting “yes” or “no” for each question. Do not leave any response blank. If one or more abnormalities are best classified as “other abnormality” select “yes” for question 209 and specify the abnormality in question 210.

**Question 211: What was the disease status?**

Indicate the disease status of MDS/MPN at the last assessment prior to the start of the preparative regimen. Refer to the MDS/MPN Response Criteria section of the Forms Instructions Manual for definitions of each disease response.

**Question 212: Specify the cell line examined to determine HI status:**

Indicate the cell line examined to determine hematologic improvement. To determine the cell line, review the Hematologic Improvement criteria listed in the MDS/MPN Response Criteria section of the Forms Instructions Manual. Continue with question 215.

**Question 213: Date of progression**

Enter the assessment date that progression from hematologic improvement was established prior to the start of the preparative regimen. Report the date of the pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear). Enter the date the sample was collected for pathological and laboratory evaluations. If extramedullary disease was detected upon radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), enter the date the imaging took place.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

**Question 214: Date of relapse:**

Enter the assessment date that relapse from complete remission was established prior to the start of the preparative regimen. Report the date of the pathological evaluation (e.g., bone marrow) or blood/serum assessment (e.g., CBC, peripheral blood smear). Enter the date the sample was collected for pathological and laboratory evaluations. If extramedullary disease was detected on radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), enter the date the imaging took place.
If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.

**Question 215: Date assessed:**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
Q216-222: Other Leukemia

**CLL** (chronic lymphocytic leukemia) is characterized by ≥ 5 × 10^9/L monoclonal lymphocytes with a CLL phenotype (usually co-expressed CD5 and CD23). The term SLL, or small lymphocytic lymphoma is used for non-leukemic cases with the tissue morphology and immunophenotype of CLL.

**Hairy cell leukemia** is characterized by the presence of abnormal B-lymphocytes in the bone marrow, peripheral blood, and spleen.

**PLL** (prolymphocytic leukemia) is a type of CLL and is characterized by increased presence of immature prolymphocytes in the bone marrow and peripheral blood.

**Questions 216-217: Specify the other leukemia classification**
Indicate the other leukemia disease classification at diagnosis. If the subtype is not listed, report as “other leukemia” and specify the reported disease.

**Question 218: Was any 17p abnormality detected?**
Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient’s disease. Testing methods you may see include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C.

Indicate if cytogenetic studies detected any 17p abnormality at any time prior to the start of the preparative regimen.

If “yes” and the disease classification is CLL, continue with question 219. If “yes” and the disease classification is PLL, continue with question 221.

If cytogenetic studies did not detect any 17p abnormality at any time prior to the start of the preparative regimen, select “no” and continue with question 219.

**Question 219: Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?**
Histologic transformation may occur after CLL diagnosis. Indicate if CLL transformed into diffuse large B-cell lymphoma (known as Richter’s transformation or Richter’s syndrome). If CLL transformed, select “yes” and continue with question 226. If CLL did not transform, select “no” and continue with question 221.
Question 220: What was the disease status?

Indicate the disease status for atypical CML at the last evaluation prior the start of the preparative regimen (or infusion of no preparative regimen was given). If no treatment was given prior to HCT, go to the signature line. Otherwise, continue with question 222.

**Disease Status of Atypical CML**

*Primary Induction Failure (PIF)*
The patient received treatment for atypical CML but never achieved complete remission at any time. PIF is not limited by the number of unsuccessful treatments; this disease status only applies to recipients who have never been in complete remission.

*Complete Remission (CR)*
All of the following criteria are met and maintained for four or more weeks:

- Marrow with normal maturation of all cellular components
- ≤ 5% blasts in the marrow
- No signs or symptoms of the disease
  - If the timeframe between achieving CR and the start date of the HCT (i.e., day 0) is less than four weeks, and the recipient is believed to be in CR, report the status at transplantation as CR.

*Important: if within four weeks following transplant the recipient’s status is determined to not be CR, an Error Correction Form must be submitted to change the pre-HCT status.*

Include recipients with persistent cytogenetic abnormalities who otherwise meet all the criteria of CR.

Report that the recipient is in CR at the time of transplant no matter how many courses of therapy it may have taken to achieve that CR.

The number of this complete remission can be determined by using the following guidelines:

- 1st CR: no prior relapse
- 2nd CR: one prior relapse
- 3rd or higher: two or more prior relapses

*Relapse (REL)*
Recurrence of disease after CR. Relapse is defined as:
• > 5% blasts in the marrow
• Extramedullary disease
• Reappearance of cytogenetic abnormalities and/or molecular markers associated with the diagnosis at levels that, as determined by a physician, represent relapse.

The number of this relapse can be determined by using the following guidelines:

• 1st relapse: one prior CR
• 2nd relapse: two prior CRs
• 3rd or higher: three or more CRs

**No treatment**
The recipient was diagnosed with atypical CML and never treated.

**Question 221: What was the disease status?**

Indicate the disease status for CLL/SLL, PLL, or hairy cell leukemia at the last evaluation prior the start of the preparative regimen (or infusion if no preparative regimen was given) and continue with question 222.

If reporting **CLL / SLL** or **PLL**, refer to the [CLL Response Criteria](#) section of the Forms Instructions Manual for definitions of each response.

**Disease Status of Hairy Cell Leukemia**¹

**Never Treated**
The recipient was diagnosed with hairy cell leukemia and never treated.

**Complete Remission (CR)**
Disappearance of all evidence of disease.
Requires **all** of the following:

• Neutrophils ≥ 1.5 × 10⁹
• Hemoglobin ≥ 12.0 g/dL
• Platelets ≥ 100 × 10⁹/L
• Absence of hairy cells on peripheral blood smear
• No palpable lymphadenopathy or hepatosplenomegaly
**Nodular Partial Remission (nPR)**
Not applicable for hairy cell leukemia.

**Partial Remission (PR)**
Requires all of the following:

- ≥ 50% reduction in the absolute hairy cell count in the peripheral blood and the bone marrow
- ≥ 50% improvement of all cytopenias
- ≥ 50% reduction in abnormal lymphadenopathy or hepatosplenomegaly

**No Response/Stable Disease (NR/SD)**
Not applicable for hairy cell leukemia.

**Progression**
Not applicable for hairy cell leukemia.

**Relapse (untreated)**
Relapse after CR:

- Reappearance of hairy cells in the peripheral blood smear and/or bone marrow (regardless of the degree of infiltration)
- Development of peripheral blood cytopenias
- Splenomegaly

Relapse after PR:

- ≥ 50% increase of residual hairy cells in the marrow
- Development of cytopenias
- Splenomegaly insufficient to qualify as PR
  OR
- Reappearance of hairy cells in the bone marrow of those patients who had been classified as partial responders based on residual splenomegaly only

---


**Other leukemia:**
To determine the disease status, use the criteria for the leukemia that most closely resembles the disease for which this form is being completed. For questions, contact your transplant center’s CIBMTR CRC.

**Question 222: Date assessed:**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. The date reported should be that of the most disease-specific assessment within the pre-transplant work-up period (approximately 30 days). Clinical and hematologic assessments include pathological evaluation (e.g., bone marrow biopsy), radiographic examination (e.g., X-ray, CT scan, MRI scan, PET scan), and laboratory assessment (e.g., CBC, peripheral blood smear), in addition to clinician evaluation and physical examination. Enter the date the sample was collected for pathological and laboratory evaluations; enter the date the imaging took place for radiographic assessments.

If the exact date is not known, use the process for reporting partial or unknown dates as described in [General Instructions, Guidelines for Completing Forms](#).
**Q223-225: Hodgkin Lymphoma**

**Hodgkin lymphoma (HL or Hodgkin disease)** is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin lymphoma are classical Hodgkin lymphoma (90-95% of cases) and nodular lymphocyte-predominant Hodgkin lymphoma (5-10% of cases).

Classical Hodgkin lymphoma can be further subdivided into four histologic subtypes: nodular sclerosis (NS), mixed cellularity (MC), lymphocyte deplete (LD), and lymphocyte rich (LR). Symptoms include the painless enlargement of lymph nodes, spleen, or other immune tissue. Generalized pruritus is also common and may precede the diagnosis by months. The most common sites of involvement include cervical, supraclavicular, and mediastinal lymph nodes. Central nervous system involvement may occur in rare cases. Other symptoms include fever, weight loss, fatigue, and/or night sweats.

Hodgkin Lymphoma (**HL**) and non-Hodgkin Lymphoma (**NHL**) are WHO disease classification subtypes of lymphoma. HL and NHL can transform into other disease subtypes. NHL can transform into other NHL subtypes, or into HL subtypes, but HL will rarely transform into NHL. Additionally, HL and NHL can occur at the same time.

In order to complete the correct Disease Classification questions for a recipient who has a history of both HL and NHL, **it is important to determine which disease is active prior to the start of the preparative regimen. A physician must make this determination.**

The following two scenarios are examples of the data reporting practice for recipients with a combination of HL and NHL.

**Scenario 1:** A recipient is being transplanted for active NHL, but has a history of HL that is in remission at the start of the preparative regimen. Report the active NHL on the Disease Classification questions, and report HL as a prior malignancy on the Pre-TED Form (Form 2400).

**Scenario 2:** A recipient is being transplanted for both active NHL and active HL. Report this as NHL using “Other B-cell Lymphoma” and specify in question 227. Complete the Disease Classification questions for NHL.

**Question 223: Specify Hodgkin lymphoma classification**

Indicate the Hodgkin lymphoma disease classification at diagnosis.
**Question 224: What was the disease status?**

Indicate the disease status at the last evaluation prior to the start of the preparative regimen. When determining the disease status, compare the restaging assessments immediately prior to the preparative regimen to the assessments at baseline. “Baseline” is defined as the disease at diagnosis or at relapse/progression.

Refer to the [Lymphoma Response Criteria](#) section of the Forms Instructions Manual for definitions of each response.

**Question 225: Date assessed:**

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. Report the date imaging took place for the radiographic assessment (CT, MRI, PET, or PET/CT). Report the date the sample was collected for pathological evaluation (e.g., bone marrow biopsy). If no radiographic or pathologic assessment was performed within one month prior to transplant, report the most recent office visit in which the physician evaluated the recipient’s disease status.

If the exact date is not known, use the process for reporting partial or unknown dates as described in [General Instructions, Guidelines for Completing Forms](#).
Non-Hodgkin lymphoma (NHL) is a large group of cancers derived from lymphocytes (white blood cells). Non-Hodgkin lymphomas can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats and weight loss. There are many different types of non-Hodgkin lymphoma. These types can be divided into aggressive (fast-growing), intermediate, or indolent (slow-growing) and can develop from either B-cells or T-cells. For the types of NHL, see the Types of Non-Hodgkin Lymphomas table in the Disease Specific Forms section.

Due to the aggressive nature of Precursor T- and Precursor B-cell lymphoblastic lymphoma (or lymphoma/leukemia), the primary disease reported for recipients with these malignancies should be acute lymphoblastic leukemia (T-cell lymphoblastic leukemia/lymphoma or B-cell ALL, NOS (L1/L2)).

Lymphomas that occur after bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas and are collectively known as post-transplant lymphoproliferative disorders (PTLD).

Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are WHO disease classification subtypes of lymphoma. HL and NHL often transform into other disease subtypes. NHL can transform into other NHL subtypes, or into HL subtypes, but HL will rarely transform into NHL. Additionally, HL and NHL can occur at the same time.

In order to complete the correct Disease Classification questions for a recipient who has a history of both HL and NHL, it is important to determine which disease is active prior to the start of the preparative regimen.

The following two scenarios are examples of the data reporting practice for recipients with a combination of HL and NHL.

Scenario 1: A recipient is being transplanted for active NHL, but has a history of HL that is in remission at the start of the preparative regimen. Report the active NHL on the Disease Classification questions, and report HL as a prior malignancy on the Pre-TED Form (Form 2400).
Scenario 2: A recipient is being transplanted for both active NHL and active HL. Report this as NHL using “Other B-cell Lymphoma” and specify in question 227, completing the Disease Classification questions for NHL.

Questions 226-227: Specify Non-Hodgkin lymphoma classification

Indicate the non-Hodgkin lymphoma disease classification at diagnosis. If the subtype is not listed, report as “other B-cell lymphoma” or “other T-cell/NK-cell lymphoma” and specify the reported disease.

If non-Hodgkin lymphoma transforms from one subtype to another, report the most current subtype. Report the initial diagnosis date of the first subtype in question 1.

Question 228: Is the non-Hodgkin lymphoma histology reported at diagnosis (question 226) a transformation from CLL?

In some cases, CLL may evolve to a more aggressive diffuse large B-cell lymphoma (DLBCL). This is commonly referred to as Richter's syndrome or Richter's transformation.

If the current histology is a transformation from CLL, indicate “yes,” continue with question 230. Also, complete the Disease Classification questions for CLL (questions 216-219).

If the current histology is not a transformation from CLL, indicate “no” and continue with question 229.

Question 229: Is the non-Hodgkin histology reported (in question 226) a transformation from, or was it diagnosed at the same time as another lymphoma (not CLL)?

Transformation may occur when a slow-growing lymphoma with an indolent clinical history changes to a more aggressive lymphoma histologically and clinically. An example of a common transformation would include follicular lymphoma evolving to a diffuse large B-cell lymphoma (DLBCL).

If a histologic transformation occurred after or concurrently with diagnosis, indicate “yes.” If a histologic transformation did not occur, indicate “no.”

Question 230: What was the disease status?

Indicate the disease status at the last evaluation prior to the start of the preparative regimen. When determining the disease status, compare the restaging assessments immediately prior to the preparative regimen to the assessments at baseline. “Baseline” is defined as the disease at diagnosis or at relapse/progression. Refer to the Lymphoma Response Criteria section of the Forms Instructions Manual for definitions of each response.
Question 231: Date assessed:

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. Report the date imaging took place for the radiographic assessment (CT, MRI, PET, or PET/CT). Report the date the sample was collected for pathological evaluation (e.g., bone marrow biopsy). If no radiographic or pathologic assessment was performed within one month prior to transplant, report the most recent office visit at which the physician evaluated the recipient’s disease status.

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
Multiple myeloma is a cancer that leads to the proliferation of malignant plasma cells (myeloma cells). Myeloma cells usually proliferate in the bone marrow. When myeloma cells grow into isolated masses in other sites, these masses are called plasmacytomas. Health problems caused by multiple myeloma can affect the bones, immune system, kidneys, and red blood cell count.

The immunoglobulins (antibodies) produced by healthy plasma cells are composed of pairs of heavy chains and light chains (see graphic below). Healthy plasma cells create many different kinds of immunoglobulins that are classified by their heavy chain type into five categories (IgG, IgA, IgM, IgD, or IgE). The light chain types are designated kappa (κ) or lambda (λ). The whole Ig molecule is then labeled IgG kappa, IgG lambda, IgA kappa, IgA lambda, etc. These protein levels can be measured in blood serum and/or urine.

Structure of an Immunoglobulin (Antibody)

Healthy plasma cells make immunoglobulins (antibodies) of all types. With the proliferation of malignant plasma cells, the level of one immunoglobulin type increases in the blood and/or urine. This abnormal immunoglobulin type is called the monoclonal immunoglobulin, monoclonal protein (M-protein/M-spike/M-
component), or paraprotein. In most cases, the normal immunoglobulins are reciprocally depressed. Patients with this condition are said to have secretory myeloma.

Some myeloma patients make only an excess of the light chain portion of the immunoglobulin molecule (i.e., only monoclonal kappa or lambda light chains). The light chain is also called Bence Jones protein. In most patients whose myeloma cells only make light chains, this paraprotein may not be detectable in the blood, but only in the urine. These patients are said to have light-chain-only disease. Ninety-seven percent of patients diagnosed with multiple myeloma have a detectable paraprotein in the blood serum and/or urine.

Distribution of Monoclonal Proteins in Secretory Multiple Myeloma12

<table>
<thead>
<tr>
<th>Monoclonal Proteins at Diagnosis</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source of monoclonal proteins</td>
<td></td>
</tr>
<tr>
<td>Serum monoclonal proteins</td>
<td>80%</td>
</tr>
<tr>
<td>Urine monoclonal proteins</td>
<td>75%</td>
</tr>
<tr>
<td>Type of monoclonal proteins</td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td>50-54%</td>
</tr>
<tr>
<td>IgA</td>
<td>20%</td>
</tr>
<tr>
<td>Monoclonal light chain (light-chain-only disease)</td>
<td>20%</td>
</tr>
<tr>
<td>IgD</td>
<td>2%</td>
</tr>
</tbody>
</table>


Nonsecretory Multiple Myeloma:
In some myeloma patients, the malignant plasma cells do not produce an excess of the heavy chain or light chain portion of the immunoglobulin molecule; therefore, a paraprotein is not detectable in the serum or urine. These patients are said to have nonsecretory myeloma (i.e., the absence of a paraprotein on immunofixation). Immunofixation detects the specific immunoglobulins after separating the proteins into bands on an electrophoresis gel. Nonsecretory myeloma accounts for 3% of myeloma cases.

Amyloidosis:
Amyloidosis is a disease in which abnormally folded proteins build up in different tissues of the body. In the
most common amyloidosis, AL amyloidosis, the abnormally folded protein is the light chain component of an immunoglobulin. These light chains may build up in a variety of tissues, but the most common sites of build-up are the heart, kidneys, liver and nerves. According to the Amyloidosis Foundation, AL Amyloidosis is a relatively rare disorder, with 1200-3200 new cases reported each year in the United States. The disease mostly impacts men and people over 40.

Accessibility verified on October 21, 2013.

Questions 232-233: Specify the multiple myeloma/plasma cell disorder (PCD) classification:

Indicate the multiple myeloma/plasma cell disorder (PCD) disease classification at diagnosis. If the subtype is not listed, report as “other plasma cell disorder” and specify the reported disease.

Plasma Cell Disorders and Characteristics

Multiple Myeloma (symptomatic)

Diagnostic criteria for symptomatic multiple myeloma requires clonal bone marrow plasma cells in ≥ 10% or biopsy proven bony or extramedullary plasmacytoma and any one or more of the following myeloma-defining events:

1. Evidence of end organ damage (i.e., CRAB features) that can be attributed to the underlying plasma cell proliferative disorder, specifically:
   - Hypercalcemia: serum calcium >1 mg/dL (> 0.25 mmol/L) higher than the ULN or > 11 mg/dL (> 2.75 mmol/L)
   - Renal insufficiency: creatinine clearance < 40 ml/min or serum creat >2 mg/dL (> 177 μmol/L)
   - Anemia: hemoglobin > 2 g/dL (> 20 g/L) below the LLN or a hemoglobin <10 g>
   - Bone lesions: one or more osteolytic lesions on skeletal x-ray, CT or PET-CT

2. Any one or more of the following biomarkers of malignancy:
   - Clonal bone marrow plasma percentage ≥ 60%
   - Involved : uninvolved serum free light chain ratio ≥ 100
   - > 1 focal lesion on MRI studies (each lesion must be ≥ 5 mm in size)

Plasma Cell Leukemia

- Peripheral blood absolute plasma cell count of at least $2.0 \times 10^9$/L (2,000 cells/mm$^3$)
- $\geq 20\%$ plasma cells in the peripheral differential white blood cell count.$^5$

Solitary Plasmacytoma (in absence of bone marrow findings diagnostic for multiple myeloma or plasma cell leukemia)

**Extramedullary:**

- No M-protein in serum and/or urine
- Extramedullary tumor of clonal plasma cells
- Normal bone marrow
- Normal skeletal survey
- No related organ or tissue impairment (end organ damage including bone lesions)

**Bone Derived**

- No M-protein in serum and/or urine
- Single area of bone destruction due to clonal plasma cells
- Bone marrow not consistent with multiple myeloma
- Normal skeletal survey (and MRI of spine and pelvis if done)
- No related organ or tissue impairment (no end organ damage other than solitary bone lesion)$^5$

*Note: if the recipient has greater than one plasmacytoma, but has not been diagnosed with another plasma cell disorder, select “other plasma cell disorder” and specify how many plasmacytomas are present and if each is bone derived or extramedullary.*

Amyloidosis

Amyloidosis is the buildup of abnormally folded proteins in various tissues of the body. Affected tissues may include the kidneys, heart, liver, gastrointestinal tract, etc. In the most common type of amyloidosis, “AL amyloidosis,” light chains from antibodies function as the amyloid protein, building up within organs and disrupting organ function. Serum and urine tests are useful for evaluating amyloidosis, but a tissue biopsy is the best way to diagnose the condition.

Osteosclerotic myeloma/ POEMS Syndrome

POEMS syndrome is poorly understood, but generally refers to p olyneuropathy, o rganomegaly, e
ndocrinopathy, M protein, and skin changes. Diagnosis may be made using the presence of the major criteria and one minor criteria below:

**Major Criteria (both of the following):**

- Polyneuropathy
- Monoclonal plasmaproliferative disorder

**Minor Criteria (at least one of the following):**

- Sclerotic bone lesions
- Castleman disease
- Organomegaly (splenomegaly, hepatomegaly, lymphadenopathy)
- Edema (edema, pleural effusion, or ascites)
- Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)
- Skin changes (hyperpigmentation, hypertrichosis, plethora, hemangiomata, white nails)
- Papilledema

**Light Chain Deposition Disease**

Similar to amyloidosis, light chain deposition disease is characterized by the overproduction and deposition of light chains in organs throughout the body; however, the organ most often affected is the kidneys. Under microscopy, the pattern of deposition and the use of staining techniques help pathologists differentiate between amyloidosis and light chain deposition disease.⁸


⁶ Osteosclerotic lesion or Castleman disease is usually present.


Accessibility verified on January 30, 2017
For recipients diagnosed with more than one PCD, either sequentially or concurrently, ensure that all applicable questions are completed.

If the recipient's disease classification is one of the following, continue with question 234.

- Multiple myeloma – IgG
- Multiple myeloma – IgA
- Multiple myeloma – IgD
- Multiple myeloma – IgE
- Multiple myeloma – IgM (not Waldenstrom macroglobulinemia)
- Multiple myeloma – light chain only

If the recipient's disease classification is the following, neither kappa nor lambda light chains will be present; therefore, continue with question 235.

- Multiple myeloma – non-secretory

If the recipient's disease classification is one of the following, continue with question 240.

- Plasma cell leukemia
- Solitary plasmacytoma (no evidence of myeloma)
- Amyloidosis
- Osteosclerotic myeloma/POEMS syndrome
- Light chain deposition disease

If the recipient's disease classification is the following, continue with question 233.

- Other Plasma Cell Disorder

**Question 234: Light Chain**

Indicate the presence of light chains as either kappa or lambda.

**Questions 235-236: What was the Durie-Salmon staging (at diagnosis)?**

Indicate Durie-Salmon stage and sub-classification at diagnosis. If this is not documented in the medical record, see the table below to determine the appropriate stage and sub-classification. If "unknown," continue with question 237.
Durie-Salmon Staging System for Multiple Myeloma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Criteria</th>
</tr>
</thead>
</table>
| I     | All of the following:  
• Hemoglobin > 10 g/dL  
• Serum calcium normal (< 10.5 mg/dL)  
• On radiograph, normal bone structure or solitary bone plasmacytoma only  
• Low M-component production rate (IgG < 5 g/dL, IgA < 3 g/dL), Urinary light chain M-component on electrophoresis (< 4 g/24 hr) |
| II    | Fitting neither stage I nor stage III |
| III   | One or more of the following:  
• Hemoglobin < 8.5 g/dL  
• Serum calcium > 12 mg/dL  
• Advanced lytic bone lesions (three or more lytic lesions)  
• High M-component product rate (IgG > 7 g/dL, IgA > 5 g/dL), Urinary light chain M-component on electrophoresis (> 12 g/24 hr) |

Sub-classification (either A or B)  
A: Relatively normal renal function (serum creatinine < 2.0 mg/dL)  
B: Abnormal renal function (serum creatinine ≥ 2.0 mg/dL)

Questions 237-239: Stage at Diagnosis: I.S.S.

Report the recipient’s lab values from diagnosis and the ISS stage of myeloma.

I.S.S. Staging System for Multiple Myeloma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>Serum β2-microglobulin &lt; 3.5 mg/L and serum albumin ≥ 3.5 g/dL</td>
</tr>
<tr>
<td>Stage II</td>
<td>Serum β2-microglobulin &lt; 3.5 mg/L and serum albumin &lt; 3.5 g/dL OR Serum β2-microglobulin 3.5 to &lt;5.5 mg/dL irrespective of serum albumin level</td>
</tr>
<tr>
<td>Stage III</td>
<td>Serum β2-microglobulin ≥ 5.5 mg/L irrespective of serum albumin level</td>
</tr>
</tbody>
</table>

Adapted from Durie BG, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-54.
Question 240: Were cytogenetics tested (conventional or FISH)?

Cytogenetics is the study of chromosomes. Cytogenetic assessment involves testing blood or bone marrow for the presence of a known chromosomal abnormality that reflects the recipient's disease. Testing methods you may see include conventional chromosome analysis (karyotyping) or fluorescence in situ hybridization (FISH). For more information about cytogenetic testing and terminology, see Appendix C.

Indicate if cytogenetic studies were obtained at any time prior to the start of the preparative regimen. If cytogenetic studies were obtained, select “yes” and continue with question 241.

If no cytogenetic studies were obtained or if it is unknown if chromosome studies were performed, select “no” or “unknown” and continue with question 262.

Question 241: Results of test:

If cytogenetic studies identified abnormalities, indicate “abnormalities identified” and continue with question 242.

If cytogenetic studies yielded “no evaluable metaphases” or there were “no abnormalities” identified, continue with question 262.

Questions 242-261: Specify abnormalities identified at any time prior to the start of the preparative regimen:

Report all abnormalities identified by all methods of cytogenetic assessment at any time prior to the start of the preparative regimen by selecting “yes” or “no” for each question. Do not leave any response blank. If one or more abnormalities are best classified as “other abnormality” select “yes” for question 260 and specify the abnormality in question 261.

Question 262: What was the disease status?

Indicate the disease status of the PCD at the last evaluation prior to the start of the preparative regimen. If the primary disease is Amyloidosis or POEMS, report “Not applicable” and go to the signature line. Otherwise, refer to the Multiple Myeloma Response Criteria section of the Forms Instruction Manual for definitions of each response.
Question 263: Date Assessed:

Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. Report the date the blood/urine was collected for the laboratory evaluations (e.g., SPEP/UPEP, serum/urine immunofixation) or report the date the bone marrow was collected for pathological evaluation. A PET scan may be used if a previous PET scan had been obtained and only in limited circumstances (e.g., plasmacytomas, lytic lesions).

If the exact date is not known, use the process for reporting partial or unknown dates as described in General Instructions, Guidelines for Completing Forms.
Questions 264-265: Specify the solid tumor classification:

Indicate the solid tumor disease classification at the time of diagnosis. Germ cell tumors that originate in the ovary or testes should be reported as *ovarian* or *testicular*, respectively. If the subtype is not listed, report as “Other solid tumor” and specify the reported malignancy in question 265. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Questions 266-267: Specify the severe aplastic anemia classification:

Indicate the severe aplastic anemia disease classification at diagnosis. If the subtype is not listed, report as “other acquired cytopenic syndrome” and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Questions 268-270: Specify the inherited abnormalities of erythrocyte differentiation or function classification

Indicate the inherited abnormalities of erythrocyte differentiation or function disease classification at diagnosis. If the subtype is not listed, report as “other constitutional anemia” or “other hemoglobinopathy” and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Q271-273: Disorders of Immune System

Questions 271-273: Specify disorder of immune system classification:

Indicate the disorder of the immune system’s disease classification at diagnosis. If the subtype is not listed, report as “other SCID” or “other immunodeficiency” and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Questions 274-275: Specify inherited abnormalities of platelets classification:

Indicate the inherited abnormalities of platelets disease classification at diagnosis. If the subtype is not listed, report as “other inherited platelet abnormality” and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Q276-277: Inherited Disorders of Metabolism

Questions 276-277: Specify inherited abnormalities of metabolism classification:

Indicate the inherited abnormalities of metabolism disease classification at diagnosis. If the subtype is not listed, report as “inherited metabolic disorder, not otherwise specified” and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Q278-279: Histocytic Disorders

Questions 278-279: Specify the histiocytic disorder classification:

Indicate the histiocytic disorder disease classification at diagnosis. If the subtype is not listed, report as “other histiocytic disorder” and specify the reported disease in question 279. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Questions 280-287: Specify autoimmune disease classification:

Indicate the autoimmune disease classification at diagnosis. If the subtype is not listed, report as "other arthritis," "other connective tissue disease," "other vasculitis," "other autoimmune neurological disorder," "other autoimmune cytopenia," or "other autoimmune bowel disorder," and specify the reported disease. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.
Q288: Other Disease

Question 288: Specify other disease:

Before using this category, check with a transplant physician to determine whether the disease can be classified as one of the listed options in the Disease Classification questions. Examples include: erythropoietic protoporphyria (EPP), and dystrophic epidermolysis bullosa (DEB).